The Enhanced Liver Fibrosis (ELF)
Hepatic fibrosis is a potentially reversible reaction of the liver to chronic hepatocyte loss from any cause. Eventually, fibrosis progresses to irreversible scarring and nodular hepatocyte regeneration termed cirrhosis. In industrialized nations alcoholism and chronic viral hepatitis (esp. Hepatitis C) are the main causes of liver fibrosis and cirrhosis.
Liver fibrosis is initiated by hepatic cell damage, which activates hepatic stellate cells (HSCs) to produce components of the extracellular matrix (ECM), resulting first in elastosis and later in fibrosis. Most common secreted ECM components are fibronectin, laminin, collagens, hyaluronic acid (HA), and proteoglycans. Collagen types I, III, IV, and V are prominently expressed within the liver; however, the HA as an essential component of the ECM is also produced primarily by HSC. The continued accumulation of ECM components progressively replaces the normal liver parenchyma with connective tissue and ultimately disrupts hepatic architecture and function. Without intervention, fibrosis of the liver usually progresses to cirrhosis, however, if the cause of hepatocyte damage is removed, fibrosis can be reversed resulting in partial or complete regeneration of liver function. The extent of liver fibrosis is therefore very important in the assessment and treatment of patients with chronic hepatic disease.
The processes of regeneration and repair are dependent on matrix metalloproteinases (MMPs) upregulation by hepatocyte damage. MMPs are a family of zinc-dependent endopeptidases capable of degrading ECM deposition and therefore central to healing and regeneration. Levels of MMPs are subject to inhibition by tissue inhibitors of metalloproteinases (TIMPs), a family of at least four proteins (TIMP 1–4) that bind MMPs. TIMP-1 overexpression can delay degradation and clearance of the ECM components, leading to progressive fibrosis. Additionally, low levels of TIMP-1 may promote HSC apoptosis as well.
Liver biopsy is the gold standard test to evaluate liver fibrosis, however, it is invasive and may result in complications, therefore a less invasive method to assess fibrosis is desirable. The Enhanced Liver Fibrosis (ELF) test measures three major components directly involved in liver matrix metabolism: HA, procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) to derive a fibrosis score. Using a cut-off of 10.2 the test is 80-90% sensitive and 40-60% specific at detecting moderate or severe fibrosis. As with other such tests (FibroSure, FibroTest, Hepascore, etc.) the ELF may have trouble discriminating mild fibrosis from more extensive disease. In addition, it may be less able to identify ongoing fibrosis without inflammation and is not specific for hepatic fibrosis since many of the same cytokines and matrix associated proteins may be produced by inflammation anywhere in the body.
- To assess the degree of fibrosis in patients at high risk for developing fibrosis or cirrhosis
- To assess the effectiveness of therapy and prognostic outcome
- Serve as a triage test to liver biopsy for fibrosis evaluation
ELF Score < 9.80 indicates lower risk of disease progression (development of cirrhosis or liver-related events)
ELF Score ≥ 9.80 – < 11.30 indicates mid risk of disease progression (development of cirrhosis or liver-related events)
ELF Score ≥ 11.30 indicates higher risk of disease progression (development of cirrhosis or liver-related events)
ELF Score < 8.90
Serum (SST tube).
Stability
- Ambient: 24 hours
- Refrigeration: 7 days
- Frozen: 1 month
- Hepatology. 2011 Jan;53(1):325-35. [PMID: 21254180]
- Br J Hosp Med (Lond). 2018 Dec 2;79(12):694-699. [PMID: 30526098]
- J Hepatol. 2013 Aug;59(2):236-42. [PMID: 23523583]
- Clin Exp Med. 2018 Feb;18(1):45-50. [PMID: 28567544]
- Liver Int. 2016 Mar;36(3):370-7. [PMID: 26104018]
- Gastroenterology. 2012 Jun;142(7):1592-609. [PMID: 22656328]
- Clin Liver Dis. 2006 Aug;10:514–534. [PMID: 17162226]
- Gastroenterology. 2008 May;134(6):1670–1681. [PMID: 18471546]
- Gastroenterology. 2004 Dec;127(6):1704-13 [PMID: 15578508]